← Markets

BridgeBio Pharma, Inc.

BBIO · NASDAQ

Market closed$81.38$1.08 (+1.35%)After hours $80.00 · -1.70%

Key statistics

Previous close$80.30
Open$79.11
Day high$82.56
Day low$78.98
52-week high$93.42
52-week low$42.09
Market cap15.94B
Volume1.31M
Average volume3.67M
P/E ratio-21.76
Forward P/E—
EPS-3.74
Dividend yield0.00%

Market context

Why it moved

BBIO edged higher amid a broader biotech sector lift, likely buoyed by acquisition activity in the space — such as AbbVie's recent $10.9 billion buyout of peer Apogee Therapeutics — even as an institutional investor disclosed a significant share sale in the company.

Investing.comMarketbeatInvestopediaFacebookFrbsf

What is happening

Recent company-specific developments and publisher coverage.

July 17, 2026BridgeBio Pharma closed modestly higher on Thursday, with shares edging up roughly 1.3% during the regular session before slipping back in after-hours trade amid broad market weakness tied to AI sentiment concerns and escalating U.S.-Iran tensions. Notably, Citigroup raised its price target on BridgeBio from $82 to $93 (while maintaining a Neutral rating), adding to a constructive analyst backdrop where the median Wall Street target sits at $98. The company's Attruby — its ATTR-CM challenger to Pfizer's Vyndamax — remains the central commercial catalyst, and UBS has highlighted biotech as a key allocation focus given improving earnings revisions and M&A tailwinds.

1.345

July 16, 2026BridgeBio Pharma closed down nearly 3% on Thursday, underperforming the broader healthcare sector (XLV) as broader market weakness dragged on biotech names amid renewed selling in AI-linked and growth stocks. The pullback comes despite a constructive backdrop for BBIO's core business: Citigroup recently raised its price target to $93 (from $82) while maintaining a Neutral rating, reflecting growing confidence in the Attruby (acoramidis) commercial launch in ATTR-CM. Analyst consensus remains broadly constructive on the company's pipeline, including BBP-418's FDA Priority Review and late-stage programs in achondroplasia and rare disease, with street targets clustering around $93–$103.

-2.8551

July 16, 2026BridgeBio Pharma closed down roughly 1.7% amid a mixed session for the broader healthcare sector, though shares rebounded sharply in after-hours trading, rising nearly 2% to around $84.27. The intraday pullback comes as investors continue to digest the competitive landscape for Attruby in the ATTR-CM market following Pfizer's April settlement extending Vyndamax patent exclusivity to mid-2031—a development analysts at Mizuho and Barclays described as removing a major overhang. Analyst consensus remains constructive, with price targets clustered near $100, underpinned by Attruby's strong commercial trajectory and a deep late-stage pipeline including BBP-418's FDA Priority Review designation.

-1.7006

July 15, 2026BridgeBio Pharma closed modestly higher, buoyed by a bullish analyst catalyst after HC Wainwright raised its price target to $120 from $110 while maintaining a Buy rating, reflecting confidence in Attruby's competitive positioning following AstraZeneca's Wainua trial failure in ATTR-CM. Investor attention is also on a $1 billion preferred equity raise led by Sixth Street and KKR's HealthCare Royalty, alongside notable insider option-exercise-and-sell transactions by two directors totaling over $14.6 million — both executed under pre-arranged 10b5-1 plans — as the stock trades near its 52-week high with an 85% one-year return.

1.2157

July 14, 2026BridgeBio Pharma fell amid a broad market selloff driven by renewed U.S.-Iran military tensions that sent oil prices surging and rattled equity sentiment, particularly in growth-oriented biotech names. Despite a constructive backdrop for the sector — Goldman Sachs recently highlighted strong biotech fundamentals and rising M&A activity, and BridgeBio added 37 new hires with RSU grants earlier this month — macro headwinds dominated the session, with the healthcare ETF (XLV) also closing lower. Shares ticked modestly higher in after-hours trading.

-3.2716

July 11, 2026BridgeBio Pharma shares tumbled nearly 5% — sharply underperforming the broader healthcare sector and a flat XLV — on heavy volume nearly double the average, suggesting a reversal following the prior session's dramatic surge of ~17%. The selloff appears to reflect profit-taking after Wednesday's rally was driven by a $1 billion convertible preferred equity financing agreement with Sixth Street and HealthCare Royalty, and new data showing acoramidis delivered early and sustained kidney-protective effects in ATTR-CM patients through Month 30. Despite the pullback, analysts maintain a constructive outlook with a median price target of $98, and the broader biotech sector continues to attract investor attention as a market leadership theme.

-4.7466

July 10, 2026BridgeBio Pharma surged on a powerful combination of catalysts: the company announced a deal for up to $1 billion in convertible preferred equity financing from Sixth Street and HealthCare Royalty, and disclosed new clinical data showing acoramidis delivered early and sustained kidney-protective effects in ATTR-CM patients through Month 30. The capital raise strengthens BridgeBio's runway as Attruby continues its commercial ramp and the company prepares for three additional potential U.S. product launches within 12 months, fueling investor conviction in both the balance sheet and pipeline. The move came amid a broader biotech tailwind, with the healthcare sector outperforming and analysts highlighting favorable M&A dynamics under current FDA leadership.

15.1155

July 9, 2026BridgeBio Pharma edged higher after-hours as fresh analyst commentary and positive pipeline coverage underscored the company's commercial momentum. Multiple Zacks reports published today examine whether Attruby's rapid ramp and upcoming drug catalysts—including anticipated approvals for encaleret, BBP-418, and infigratinib in 2026–2027—justify the current valuation, while a comprehensive SWOT analysis highlighted 355% year-over-year revenue growth and a clear path to profitability above $600M by 2028. Jefferies maintained its Buy rating with a $100 target, and Jim Cramer's recent call labeling biotech the "hottest group in the market" added tailwinds, even as a broader risk-off session weighed on the S&P 500 amid renewed U.S.-Iran tensions.

0.5391

富途牛牛 · July 16, 2026Citi Maintains BridgeBio Pharma(BBIO.US) With Hold Rating, Raises Target Price to $93Simply Wall Street · May 30, 2026BridgeBio Priority Review Puts BBP-418 And Valuation In Investor FocusMuscular Dystrophy News · March 31, 2026Bridgebio asks FDA to approve potential 1st treatment for LGMD2iQuiver Quantitative · March 10, 2026BridgeBio Pharma shares jump as investors focus on fresh BBP-418 data at MDA meeting and near-term regulatory milestones | BBIO Stock News
Benzinga · July 16, 2026Citigroup Maintains Neutral on BridgeBio Pharma, Raises Price Target to $93
Benzinga · July 2, 2026BridgeBio Announces Publication Of New Analyses In Circulation: Heart Failure, Examining Kidney Function In Individuals With Transthyretin Amyloid Cardiomyopathy Treated With Acoramidis
Mt Newswire · July 1, 2026BridgeBio Pharma Announces $1 Billion Convertible Preferred Equity Deal
Benzinga · July 1, 2026BridgeBio Pharma Agrees To Sell Up To $1B Of Convertible Preferred Stock To Sixth Street And KKR's HealthCare Royalty
Mt Newswire · July 1, 2026Market Chatter: KKR, Sixth Street to Invest $1 Billion in BridgeBio Preferred Equity
Mt Newswire · June 29, 2026Sector Update: Healthcare Stocks Edge Higher Premarket Monday
Mt Newswire · June 29, 2026BridgeBio Pharma Meets Primary Endpoint For Achondroplasia Drug in Phase 3 Trial
Benzinga · June 29, 2026Reported Sunday, BridgeBio PROPEL 3 Phase 3 Trial Published In NEJM, Oral Infigratinib Demonstrates Statistically Significant Improvements In Height, Body Proportionality In Achondroplasia

Peers

S&P 500SPX · $7,457.69-1.01%Roivant Sciences Ltd.ROIV · $34.51+1.71%Revolution Medicines, Inc.RVMD · $186.16+3.90%Halozyme Therapeutics, Inc.HALO · $77.81+0.35%Ascendis Pharma A/SASND · $261.00+0.46%Neurocrine Biosciences, Inc.NBIX · $170.88-0.39%BioMarin Pharmaceutical Inc.BMRN · $59.59-0.68%Ionis Pharmaceuticals, Inc.IONS · $54.39-0.48%Alnylam Pharmaceuticals, Inc.ALNY · $267.47-5.54%Exelixis, Inc.EXEL · $55.92+0.43%Grifols, S.A.GRFS · $7.27-0.82%Takeda Pharmaceutical Company LimitedTAK · $17.15+2.51%